We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+13.7%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$7.5M
Cap. Flow
-$18.1M
Cap. Flow %
-5.36%
Top 10 Hldgs %
55.99%
Holding
39
New
12
Increased
4
Reduced
11
Closed
12

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$26.9M
2
A icon
Agilent Technologies
A
+$16.5M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
LLY icon
Eli Lilly
LLY
+$15.6M
5
SWTX
SpringWorks Therapeutics
SWTX
+$14.1M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.5M
2
MRK icon
Merck
MRK
+$21.7M
3
AMGN icon
Amgen
AMGN
+$20.1M
4
BIIB icon
Biogen
BIIB
+$17.8M
5
KVUE icon
Kenvue
KVUE
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
26
DELISTED
Avadel Pharmaceuticals
AVDL
$5.05M 1.49%
385,172
-347,829
-47% -$5.3M
IONS icon
27
Ionis Pharmaceuticals
IONS
$9.06B
$3.9M 1.15%
97,300
-62,866
-39% -$2.92M
AMGN icon
28
Amgen
AMGN
$210B
– –
-64,201
Closed -$20.1M
AVTR icon
29
Avantor
AVTR
$9.25B
– –
-400,000
Closed -$8.48M
BIIB icon
30
Biogen
BIIB
$29.8B
– –
-76,726
Closed -$17.8M
BMRN icon
31
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-273,533
Closed -$22.5M
CRSP icon
32
CRISPR Therapeutics
CRSP
$4.88B
– –
-201,497
Closed -$10.9M
CYTK icon
33
Cytokinetics
CYTK
$10.7B
– –
-236,900
Closed -$12.8M
EOLS icon
34
Evolus
EOLS
$398M
– –
-465,300
Closed -$5.05M
KVUE icon
35
Kenvue
KVUE
$37.5B
– –
-960,400
Closed -$17.5M
MRK icon
36
Merck
MRK
$316B
– –
-175,600
Closed -$21.7M
PFE icon
37
Pfizer
PFE
$145B
– –
-185,200
Closed -$5.18M
SRPT icon
38
CALL
Sarepta Therapeutics
SRPT
$1.68B
– –
-20,000
Closed -$3.16M
TEVA icon
39
Teva Pharmaceuticals
TEVA
$40.2B
– –
-911,900
Closed -$14.8M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Cutter Capital Management held 39 positions worth $339M, up 2.3% from $331M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Cutter Capital Management withdrew a net $18.1M in Q3 2024, closing 12 positions and reducing 11 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Consumer Staples.

Against the trend, Cutter Capital Management opened a new position in Bristol-Myers Squibb worth $29.7M.

  • Cutter Capital Management's largest Q3 2024 buy was Bristol-Myers Squibb: 574,057 shares worth $29.7M.
  • Cutter Capital Management added most to Perrigo in Q3 2024, an estimated $12.6M increase.
  • Cutter Capital Management's biggest Q3 2024 reduction was BioCryst Pharmaceuticals, cutting an estimated $8.95M.
  • Cutter Capital Management fully exited BioMarin Pharmaceuticals in Q3 2024, selling an estimated $22.5M.
  • Cutter Capital Management's ten largest holdings make up 56% of its $339M portfolio in Q3 2024.
  • Cutter Capital Management opened 12 new positions and closed 12 in Q3 2024.
  • Cutter Capital Management's portfolio value rose 2.3% quarter-over-quarter to $339M.

Based on Cutter Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.